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ABSTRACT
Objectives: There is controversy about the effects of
non-steroidal anti-inflammatory drugs (NSAIDs) on cardi-
ovascular disease (CVD) mortality. The aim of this study
was to explore associations between NSAID use and
mortality in patients with inflammatory polyarthritis (IP).
Subjects and methods: A total of 923 patients with
new onset (IP), recruited to the UK Norfolk Arthritis
Register (NOAR) between 1990–1994, were followed up
to the end of 2004. Current medication was recorded
annually for the first 6 years and then every 2–3 years.
Rheumatoid factor (RF) and C-reactive protein (CRP) were
measured. Logistic regression was used to calculate all
cause and CVD mortality odds ratios (OR) for NSAID use
at baseline and during follow-up, adjusting for gender and
time-varying covariates: RF, CRP, joint counts, smoking,
steroid use, DMARD use and other medication use.
Results: By 2004 there were 203 deaths, 85 due to CVD.
At baseline, NSAIDs were used by 66% of patients. In
final multivariate models, baseline NSAID use was
inversely associated with all cause mortality (adjusted OR
0.62, 95% CI 0.45 to 0.84) and CVD mortality (adjusted
OR 0.54, 95% CI 0.34 to 0.86). Interval NSAID use had
weaker mortality associations: all cause mortality
(adjusted OR 0.72, 95% CI 0.52 to 1.00), CVD mortality
(adjusted hazard ratio (HR) 0.66, 95% CI 0.40 to 1.08).
Conclusion: No excess CVD or all cause mortality was
observed in NSAID users in this cohort of patients with IP.
This is at variance with the literature relating to NSAID
use in the general population. It is unclear whether this
represents unmeasured confounders influencing a doc-
tor’s decision to avoid NSAIDs in the treatment of IP.
Patients with rheumatoid arthritis (RA) experience
increased rates of myocardial infarction and death
from cardiovascular disease (CVD) when compared
to the general population.
12The reasons for this
increased CVD mortality and morbidity in associa-
tion with chronic inflammatory joint disease is
currently the subject of much research. Chronic
inflammation may contribute to the progression of
atherosclerosis in these patients.
3 Reduction of
inflammation by use of disease-modifying anti-
rheumatic drugs (DMARDs) may be associated
with reduced rates of CVD events in RA.
4–6
However, other medications commonly used in
the treatment of inflammatory arthritis may
adversely affect the cardiovascular system.
There is great interest in the CVD side-effects of
non-selective non-steroidal anti-inflammatory
drugs (NSAIDs) and selective cyclo-oxygenase-2
(COX2) inhibitors. It is accepted that these drugs
have the potential to increase CVD risk, in the
general population, by increasing systolic blood
pressure
7 and exacerbating existing congestive
heart failure
8 and there is concern over the
thrombotic potential of highly selective COX2
inhibition. Use of the non-selective NSAID,
naproxen, was associated with reduced rates of
CVD events in patients with RA
91 0 and meta-
analysis of observational studies has suggested a
CVD protective association with naproxen.
11 12
There is little evidence for a primary cardiac
protective effect of other non-selective NSAIDs in
the general population.
Patients with chronic inflammatory polyarthritis
(IP) use NSAIDs for symptom control, often over
long periods of time and usually in combination
with DMARDs. Given that patterns of NSAID use
may be different in this patient group than in the
general population, the aim of this study was to
explore whether NSAID use was associated with
cardiovascular mortality in patients who have IP.
METHODS
Study population
This study utilised data from the Norfolk Arthritis
Register (NOAR).
13 This is a primary care based
inception cohort of patients who presented with
signs and symptoms of IP. Patients with synovitis
affecting two or more peripheral joints, lasting for
>4 weeks are eligible for assessment. Patients are
visited in the home setting by a research nurse who
conducts a structured interview, recording pre-
scribed medications and patient use of over the
counter (OTC) drugs. This medication history was
used to estimate comorbidity with the number and
types of medication used to quantify comorbid
disease burden. Smoking status is recorded at each
assessment and recorded as current, ex-smoker, or
never smoker.
A joint examination is conducted and a blood
sample is obtained for measurement of rheumatoid
factor (RF) and C-reactive protein (CRP) concen-
tration. Patients complete a modified Health
Assessment Questionnaire (HAQ) at each assess-
ment. Subjects with definite inflammatory syno-
vitis, who are not subsequently diagnosed by a
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from rheumatoid arthritis, psoriatic arthritis, postviral arthritis
and undifferentiated inflammatory polyarthritis, are eligible for
inclusion on the register and are followed longitudinally.
Subsequent assessments occur annually for the first 5 years of
the study. After this, assessments occur every 2 years.
NSAID exposure
NSAID use at the start of each interval of follow-up was
determined from the current medication history obtained by the
research nurse during each assessment. NSAID use prior to the
baseline assessment was not recorded. NSAID exposure
included OTC NSAIDs as well as doctor-prescribed NSAIDs.
However, dosages, frequency and dates of starting and stopping
NSAIDs were not recorded. Baseline NSAID use, ever reporting
NSAID use in the study and time-varying NSAID exposure
during the follow-up assessments were recorded. We did not
record whether patients had been exposed to NSAIDs in the
interim months between assessments.
Outcome measures
All patients included on the register were flagged on the UK
National Health Service Central Register. Death notification
and death certificates were provided for study participants who
died in the UK. The underlying cause of death was grouped
according to the International Classification of Diseases, 9th
revision (ICD-9).
14 Death was attributed to CVD if the main
cause of death was issued with ICD9 codes 393–459.
Analysis
Relationships between NSAID use and all cause and CVD
mortality were explored using logistic regression. Mortality
outcomes were explored in baseline NSAID users compared to
non-NSAID users at baseline. Patients who were identified as
never having used NSAIDs throughout the period of the study
were compared to those patients who were identified as NSAID
users at any NOAR assessments. Initially univariate analyses
were undertaken. Subsequent analyses were undertaken by
pooling data across all subjects and then adjusting for age and
gender. Multivariate analyses were undertaken to determine the
independent effect of NSAID use on all cause and cardiovascular
mortality. The models were adjusted for gender, age and time-
varying covariates recorded at the study assessments, including
smoking status, CRP tertiles, RF, rheumatoid nodules, joint
counts, morning stiffness, disability (HAQ), corticosteroids,
DMARDs, number of comorbid medications used and use of
medication to treat CVD. In addition NSAID use was treated as
a time-varying exposure and the relationship between NSAID
use and mortality was explored for each interval of follow-up.
This was performed univariately and multivariately adjusting
for time-varying covariates including disease variables, medica-
tion and smoking status. The analyses were repeated for the
subgroup of patients who cumulatively met 1987 American
College of Rheumatology (ACR) classification criteria for RA.
RESULTS
A total of 923 subjects recruited to NOAR between 1990 and
1994 were eligible for study. Complete mortality follow-up was
obtained for the cohort up to the end of December 2003. The
median follow-up period was 10.7 years (interquartile range
(IQR) 9.4 to 12.2).
At the baseline assessment 613 (66.4%) patients were NSAID
users and a further 141 (15.3%) patients were identified as using
NSAIDS during the follow-up assessments. Of these 754 ever
NSAID users, NSAID use was reported at the start of 58% of
follow-up intervals. A total of 169 (18.3%) patients reported no
NSAID exposure at any of the study assessments. The mean
duration of NSAID exposure during the period of this study,
estimated from the number of study assessments where NSAID
use was reported, was 4 years.
Baseline demographic and clinical disease characteristics of
the cohort stratified by baseline NSAID use are shown in table 1.
The median age at disease onset was 55 years in NSAID users
and non-users, and the proportion of female patients was
similar in both groups. Approximately two-thirds of the
Table 1 Baseline variables by baseline NSAID use among patients with
IP
Not baseline NSAID
user n=310, n (%) or
median (IQR)
Baseline NSAID
user n=613, n (%)
or median (IQR) p Value
Demographics and social
history:
Age 55 (41 to 69) 55 (42 to 66) 0.62
Female 207 (66.8) 392 (64.0) 0.39
Lower social class .3b* 140 (47.5) 283(48.1) 0.85
Ever smoker 200 (64.5) 428 (69.8) 0.10
Current smoker 88 (28.4) 165 (26.9) 0.64
Comorbid drug use:
1–2 Comorbid conditions 115 (37.1) 211 (34.4) 0.41
>3 Comorbid conditions 13 (4.1) 25(4.1) 0.38
1 CVD drug 33 (10.6) 56 (9.1) 0.41
>2 CVD drugs 27 (8.7) 44 (7.2) 0.36
Aspirin 17 (2.8) 14 (4.5) 0.19
Antihypertensive
medication
46 (14.8) 92 (15.0) 0.94
Heart failure medication 53 (17.1) 91 (14.9) 0.61
IHD medication 40 (12.9) 72 (11.8) 0.85





163(52.6) 305 (49.8) 0.42
Morning stiffness
>60 min
104 (33.5) 257 (41.9) 0.01
Swollen joint count 5 (2 to 11) 8 (3 to 14) ,0.01
Tender joint count 6 (2 to 14) 9 (3 to 19) ,0.01
CRP >5 mg/litre 133 (42.9) 350 (57.1) ,0.01
Rheumatoid factor
positive
72 (23.2) 209 (34.1) ,0.01
RA (by ACR criteria) 128 (41.3) 324 (52.9) ,0.01
Rheumatoid nodules 17 (5.5) 58 (9.5) 0.04
HAQ 0.5 (0.125 to 1.25) 0.875 (0.375 to 1.5) ,0.01
DMARDs 44(14.2) 110(17.9) 0.14
Methotrexate 2 (0.7) 12 (2.0) 0.21
Hydroxychloroquine 2 (0.65) 5 (0.82) 0.78
Steroids 37 (11.9) 37 (6.04) ,0.01
*Social class only available for 880 patients.
ACR, American College of Rheumatology; CRP, C-reactive protein; CVD, cardiovascular
disease; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment
Questionnaire; IHD, ischaemic heart disease; IQR, interquartile range; IP, inflammatory
polyarthritis; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.
Table 2 Mortality in patients with inflammatory polyarthritis
Men (n=324) Women (n=599) All (n=923)
All causes, n (%) 108 (33.3) 95 (15.9) 203 (22.0)
Cardiovascular, n (%) 44(13.6) 41 (6.8) 85 (9.2)
Respiratory, n (%) 16 (4.9) 12 (2.0) 28 (3.0)
Neoplastic, n (%) 34 (10.5) 20 (3.3) 54(5.8)
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mined by current drug use, was remarkably similar between
NSAID users and non-users with approximately 1 in 10 taking a
cardiovascular drug at disease entry. Patients who were using
NSAIDs had markers of more severe inflammatory joint disease
at baseline. NSAID users were more likely to be RF positive,
have rheumatoid nodules and a higher HAQ score at baseline.
They also had higher CRP concentrations and had clinical
evidence of more active inflammatory joint disease with higher
swollen and tender joint counts, and more prolonged morning
stiffness than non-NSAID users. DMARD use at baseline was
low and similar in both groups. At baseline 41% of the cohort
met ACR classification criteria for RA. This rose to 67% when
the criteria were applied cumulatively throughout the study.
During the period under study only 41 patients were treated
with selective COX2 inhibitors at any time. This exposure was
limited to the last 2 years of the study period. During the study,
diclofenac was used most frequently, identified in 27% of the
NSAID exposures during the study, followed by naproxen 17%
and ibuprofen 17%. Other less frequently used drugs included
ketoprofen, indomethacin, piroxicam, meloxicam and nabume-
tone. Switching between NSAIDs was frequently observed
during the follow-up period.
Patients were followed up to the end of 2003 with a median
follow-up period of 10.1 years (interquartile range 9.3 to 10.8).
Over this time period there were 203 deaths (table 2).
Approximately twice the proportion of males died as females.
Cardiovascular disease was identified as the underlying cause of
death in 85 participants.
The univariate relationship between NSAID exposure and
subsequent all-cause and cardiovascular mortality by gender is
shown in table 3. There was a trend for baseline NSAID use to
be associated with reduced all cause and CVD mortality.
Patients who ever used NSAIDs during the study had a lower
risk of death than non-NSAID users (odds ratio (OR) 0.62) and
this was most marked for CVD mortality (OR 0.48). Figure 1
demonstrates the Kaplan Meier survival estimates for cardio-
vascular mortality by ever use of NSAIDs. Time-varying NSAID
exposure was explored univariately and a similar inverse
relationship was observed with all cause mortality (OR 0.58)
and CVD mortality (OR 0.51).
The multivariate analyses are shown in table 4. The final
models examining the association between NSAID use and all
cause mortality were adjusted for gender and time-varying
covariates for each interval of follow-up. Baseline NSAID use
(adjusted OR (ORadj) 0.62, 95% CI 0.45 to 0.84) and ever use of
NSAIDs (ORadj 0.52, 95% CI 0.36 to 0.76) were associated with
reduced risk of all cause mortality. Baseline NSAID use was
associated with reduced risk of CVD mortality (ORadj 0.54, 95%
CI 0.34 to 0.86). Ever use of NSAIDs during follow-up was also
significantly associated with a reduced risk of CVD mortality
(adjusted hazard ratio (HRadj) 0.38, 95% CI 0.23 to 0.66). Time-
varying NSAID exposure was associated with a trend for
reduced all cause mortality (OR 0.72, 95% CI 0.52 to 1.00) and
CVD mortality (OR 0.66, 95% CI 0.40 to 1.09) during each
interval of follow-up, but neither reached statistical significance.
Repeating the analyses in the subgroup of patients with RA did
not reveal differences to that in the IP cohort.
In secondary analyses NSAID exposure was examined to
explore whether increasing duration of NSAID exposure was
associated with reduced CVD mortality. The duration of
NSAID exposure covariate was entered into the multivariate
logistic model predicting CVD mortality. Longer duration of
NSAID use was not associated with a significant reduction in
CVD mortality risk in those patients exposed to NSAIDs during
this study (OR 1.0, 95% CI 0.86 to 1.15) for each additional
period of NSAID exposure.
To assess the possibility that the association between
NSAIDs and mortality was mediated by confounding, we
explored baseline covariates associated with use of NSAIDs
during the study. Variables associated with more severe disease,
including RF, DMARDs, elevated CRP and swollen joint counts,
were found to be independently associated with use of NSAIDs
in multivariate logistic models (table 5). There was an inverse
association between use of corticosteroid medication and
NSAID use (OR 0.44, 95% CI 0.35 to 0.55), but corticosteroids
Figure 1 Cardiovascular mortality: Kaplan-Meier survival estimates, by
ever use of non-steroidal anti-inflammatory drug (NSAID).




All cause mortality CVD mortality
Univariate,
OR (95% CI)








All 923 5634 0.73 (0.55 to 0.99) 0.81 (0.60 to 1.03) 0.67 (0.43 to 1.04) 0.73 (0.48 to 1.15)
Females 599 3742 0.86 (0.56 to 1.32) 0.86 (0.55 to 1.32) 0.55 (0.30 to 1.02) 0.54 (0.29 to 1.02)
Males 324 1892 0.61 (0.41 to 0.92) 0.74 (0.50 to 1.12) 0.79 (0.42 to 1.47) 0.94 (0.50 to 1.78)
Ever NSAID
use
All 923 5634 0.62 (0.44 to 0.86) 0.70 (0.50 to 1.00) 0.48 (0.29 to 0.77) 0.54 (0.33 to 0.88)
Females 599 3742 0.74 (0.44 to 1.22) 0.81 (0.48 to 1.36) 0.42 (0.22 to 0.82) 0.46 (0.23 to 0.90)
Males 324 1892 0.49 (0.31 to 0.77) 0.61 (0.39 to 0.98) 0.50 (0.25 to 1.01) 0.62 (0.31 to 1.27)
Time-varying
NSAID use
All 923 5634 0.58 (0.43 to 0.78) 0.66 (0.49 to 0.90) 0.51 (0.32 to 0.81) 0.58 (0.37 to 0.93)
Females 599 3742 0.60 (0.39 to 0.91) 0.68 (0.44 to 1.05) 0.50 (0.26 to 0.97) 0.58 (0.30 to 1.12)
Males 324 1892 0.54 (0.36 to 0.81) 0.65 (0.43 to 0.98) 0.51 (0.27 to 0.94) 0.59 (0.31 to 1.12)
CVD, cardiovascular disease; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio.
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Ann Rheum Dis 2009;68:367–372. doi:10.1136/ard.2007.076760 369were not associated with all cause mortality or CVD mortality
in the multivariate models. Use of drugs to treat CVD
comorbidity was inversely associated with NSAID use.
A sensitivity analysis was conducted to explore the strength
of residual confounding that would be required to explain the
observed association between non-NSAID use and CVD
mortality.
15 Avoidance of NSAIDs, observed in 18% of this
cohort, was associated with CVD mortality (ORadj 2.6, 95% CI
1.5 to 4.3). If we assume a prevalence of the unmeasured
confounder is 20%, a single residual confounder would have to
have to be very strongly associated with NSAID avoidance (OR
4.0) and cardiovascular mortality (relative risk 4.0) to reduce the
lower CI value from 1.5 to 1.0. It is difficult to think of potential
confounders that might have such strong associations with
NSAID avoidance and CVD mortality.
CONCLUSIONS
In this cohort of patients with early IP, NSAID use was not
found to be associated with increased risk of all cause mortality
or cardiovascular mortality. Patients who were exposed to
NSAIDs tended to have a reduced risk of dying than the study
patients who did not receive NSAIDs. This relationship was
particularly strong for cardiovascular mortality and, ever being
exposed to NSAIDs was associated with a 2.5-fold reduction in
risk of cardiovascular death. However, increasing duration of
NSAID exposure was not found to be associated with greater
reductions in CVD mortality.
These findings are somewhat surprising given the results
from other studies. Several clinical trials have demonstrated a
higher risk of adverse CVD outcomes for patients treated with
selective COX2 inhibitors compared to placebo.
11 16–18 In addi-
tion, epidemiological studies have raised concerns over the
cardiovascular safety of non-selective NSAIDs.
19–22 These studies
examined cardiovascular outcomes in large population based
groups. There is little data reported on NSAID associations with
cardiovascular events within cohorts of patients with chronic
inflammatory disease. A small cardioprotective effect has been
observed in some studies with use of naproxen
91 1 and
ibuprofen.
23 A recent meta-analysis of nine randomised con-
trolled trials in patients with osteoarthritis and rheumatoid
arthritis found that use of non-selective NSAIDs, compared to
placebo, had a combined odds ratio for CVD events of 0.6 (95%
CI 0.2 to 1.7).
24 Naproxen use was associated with similar risk of
CVD events to that observed with other non-selective NSAIDs.
The number of events reported by these studies was low and
the authors conclude that use of NSAIDs had no significant
effect on cardiovascular events in patients with joint disease.
24
Therefore our finding of reduced risk of CVD mortality in
patients with inflammatory arthritis using NSAIDs warrants
further discussion.
Inflammation is a strong predictor of future CVD mortality
in early IP
25 and in RA.
32 6In this study markers of inflamma-
tion, including joint counts and baseline CRP, were higher in
patients who used NSAIDs. However, there were no significant
interactions between NSAID use and baseline CRP concentra-
tion in the multivariate regression models.
We know that inflammation is associated with modification
of eicosanoids with increased generation of thromboxane A2
and prostacyclin. COX1 derived thromboxane A2 promotes
platelet aggregation and vasoconstriction while COX2 driven
endothelial prostacyclin production reduces the effects of
thromboxane A2 by triggering vasodilatation and inhibiting
platelet aggregation.
27 Atherosclerotic lesions are rich in cells
that express the COX2 enzyme that may be implicated in
atherosclerotic plaque destabilisation and the development of
CVD events.
28 It is possible that the use of NSAIDs in patients
with chronic inflammation influences the eicosanoid pathway
to produce a net beneficial effect on the cardiovascular system.
In our study we failed to show any further CVD benefit from
increasing duration of NSAID exposure. This suggests that
NSAID-induced eiconanoid modification was unlikely to be
responsible for the favourable CVD mortality outcome. A
limitation of this study was that NSAID exposure was not
accurately measured as dosage and actual time on each
treatment were not recorded. Therefore it is difficult to
interpret whether increased NSAID exposure actually influences
CVD mortality.
In clinical trials it has been demonstrated that regular use of
high-dose naproxen induces suppression of platelet thrombox-
ane similar to that seen with low-dose aspirin,
29 and this lends
plausibility to a cardioprotective effect of this drug. Other non-
selective NSAIDs may have similar antiplatelet effects to




adjusted OR (95% CI)
CVD mortality, adjusted
OR (95% CI)
Baseline NSAID All IP 5634 0.62 (0.45 to 0.84) 0.54 (0.34 to 0.86)
RA 3791 0.65 (0.45 to 0.93) 0.69 (0.39 to 1.20)
Ever NSAID All IP 5634 0.52 (0.36 to 0.76) 0.38 (0.23 to 0.66)
RA 3791 0.61 (0.38 to 0.98) 0.53 (0.27 to 1.06)
Time-varying NSAID use All IP 5634 0.72 (0.52 to 1.00) 0.66 (0.40 to 1.09)
RA 3791 0.75 (0.52 to 1.08) 0.86 (0.49 to 1.49)
RA status refers to cumulative RA status by the sixth assessment. Final multivariate model adjusted for time-varying age, gender,
RF, RA status, nodules, tertiles of swollen and tender joint counts, CRP, HAQ, number of medications other than arthritis
medication, number of CVD medications, corticosteroid use, methotrexate use and other DMARD use, smoking history
CRP, C-reactive protein; CVD, cardiovascular disease; DMARD, disease-modiftying antirheumatic drug; HAQ, Health Assessment
Questionnaire; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; IP, inflammatory polyarthritis; RA, rheumatoid arthritis;
RF, rheumatoid factor.
Table 5 Multivariate analysis: baseline predictors of NSAID use during
study
OR (95% CI)
Swollen joint count/(tertiles) 1.15 (1.08 to 1.23)
RF positive 1.53 (1.35 to 1.73)
Use of DMARDs 1.39 (1.20 to 1.61)
CRP (tertile) 1.13 (1.06 to 1.21)
Use of any CVD drugs 0.66 (0.57 to 0.77)
Steroid use 0.44 (0.35 to 0.55)
CRP, C-reactive protein; CVD, cardiovascular disease; DMARD, disease-modifying
antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio;
RF, rheumatoid factor.
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30 However, population based observational studies have
failed to show cardioprotective effects of these drugs.
31 NSAIDs
tend to be used regularly in the treatment of symptoms of
inflammatory arthritis. However, dosage and frequency of
NSAIDs were not recorded in this study and many patients
changed NSAIDs during follow-up. Naproxen was used in only
17% of NSAID exposures identified and it seems unlikely that
the cardioprotective association observed in this study was due
to an effect of naproxen alone. The most frequently used
NSAID during the period of this study was diclofenac, which
has been shown in other studies to have a CVD risk similar to
that seen with selective COX2 inhibitors.
32 33
A major limitation of this study was the potential inaccuracy
in assigning NSAID exposure. It is highly likely that several
patients, categorised as ‘‘never’’ exposed to NSAIDs during this
study, will have used NSAIDs either prior to their baseline
assessment or during the interim period between their assess-
ments. In the UK, patients with chronic inflammatory arthritis
are often encouraged to use NSAIDs for symptom control. It is
likely that frequent users of NSAIDs will include NSAIDs in
their current medication that is recorded by the nurses
conducting the home-based interviews. Therefore, although
NSAID exposures were not recorded accurately in this observa-
tional study, the finding of higher death rates in patients with
IP who do not frequently use NSAIDs is an important study
finding that contributes to the research literature in this area.
This should prompt further study examining NSAID associa-
tions with CVD outcomes in inflammatory arthritis.
Another possible explanation for our findings includes the
effects of unmeasured confounders. This longitudinal study has
enabled examination of the effects of NSAID exposure on
mortality with adjustment for variables measuring the severity
of the inflammatory joint disease, inflammation, smoking and
comorbidity. However, unmeasured factors may have influ-
enced the decision to use an NSAID and the risk of mortality.
The sensitivity analysis revealed that a single unmeasured
confounder would have to be very strongly associated with
NSAID use and mortality. It is possible that multiple
unmeasured confounders may act together to produce this size
of effect. Patient characteristics that are difficult to quantify, for
example frailty, may have led to avoidance of NSAID use in
these patients. In this situation NSAID use might indicate more
healthy participants who have better CVD survival.
Doctor prescribing habits are difficult to determine. At the time
of this study there was little evidence to suggest that NSAIDs
should be avoided in patients at high risk of CVD. Therefore, it is
unlikely that doctors systematically avoided NSAID prescriptions
for patients with increased CVD risk. Another limitation of this
study was that comorbidity was not recorded. However, CVD
medication, antiplatelet medication and cholesterol lowering
medication were recorded at the baseline and annual assessments
and this provided a proxy measure for CVD comorbidity. In the
propensity model (table 5), CVD medication use was identified as
having an inverse association with NSAID use. This might
support doctor-channeling of NSAIDs away from frail patients
with CVD thereby explaining this paradoxical relationship
between NSAID use and reduced CVD mortality outcome.
However, the multivariate analysis revealed that the NSAID
mortality association persisted even after adjusting for CVD
medication use.
Therefore the finding of reduced CVD mortality in patients
with IP treated with NSAIDs is interesting but difficult to
explain. It may represent channeling of NSAIDs away from
vulnerable patients rather than a true cardioprotective effect of
the NSAID drug. However, this study suggests that the
increased CVD risk observed in patients with IP is unlikely to
be due to the effects of NSAIDs.
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